Molecular biology

The 2023 WLA Prize Award Ceremony to be Held in Shanghai on Nov. 6

Retrieved on: 
Wednesday, November 1, 2023

The World Laureates Association Prize (WLA Prize) is an international science prize established in Shanghai, in 2021, initiated by the World Laureates Association (WLA),  managed by the WLA Foundation, and exclusively funded by HongShan.

Key Points: 
  • The World Laureates Association Prize (WLA Prize) is an international science prize established in Shanghai, in 2021, initiated by the World Laureates Association (WLA),  managed by the WLA Foundation, and exclusively funded by HongShan.
  • Each year, the WLA Prize is awarded in two categories: "Computer Science or Mathematics" and "Life Science or Medicine", with the total award for each Prize being RMB 10 million.
  • The 2023 WLA Prize in Computer Science or Mathematics recognizes two scientists: Arkadi Nemirovski, the John P. Hunter, Jr.
  • Continuing last year's tradition, the ceremony will be held at the Opening Ceremony of the 6th WLA Forum, an annual scientific event which also features WLA Prize related academic lectures and dialogues starting from Nov. 5.

The 6th WLA Forum Will Embark on New Journey in Shanghai

Retrieved on: 
Monday, October 30, 2023

The Award Ceremony of the 2023 WLA Prize will be held on November 6 at the opening ceremony of the 6th WLA Forum.

Key Points: 
  • The Award Ceremony of the 2023 WLA Prize will be held on November 6 at the opening ceremony of the 6th WLA Forum.
  • Under the annual theme "Science Leads Transformation," the 6th WLA Forum introduces several notable enhancements to its dynamic program – a new chairmanship to the WLA featured forums, such as the WLA Life Science Forum, WLA Intelligent Science Forum, WLA Zero Carbon Forum, WLA Young Scientists Forum, etc.
  • Additionally, a new academic lecture series, the WLA Frontier Lectures, featuring approximately 60 scholarly presentations that showcase cutting-edge research progress will be launched at the 6th WLA Forum.
  • The five laureates of the 2023 WLA Prize announced last month will attend the 6th WLA Forum in person.

Recognizing and Celebrating Outstanding Contributions to the Canadian Cancer Research Community

Retrieved on: 
Monday, November 6, 2023

TORONTO, Nov. 6, 2023 /CNW/ - Today, the Canadian Cancer Research Alliance (CCRA) announces the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.

Key Points: 
  • TORONTO, Nov. 6, 2023 /CNW/ - Today, the Canadian Cancer Research Alliance (CCRA) announces the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.
  • Awardees will be honoured at the Canadian Cancer Research Conference, which is taking place in Halifax from November 12 to 14.
  • Initiated in 2011, the CCRA Awards acknowledge and celebrate the contributions of individuals who have had a remarkable impact on cancer research and the cancer research community, as well as those who have shown exceptional leadership in patient involvement in cancer research.
  • The Canadian Cancer Research Alliance (CCRA) is an alliance of organizations that collectively fund most of the cancer research conducted in Canada – research that will lead to better ways to prevent, diagnose, and treat cancer, and improve patient and survivor outcomes.

Global Protein Labeling Market Size, Share & Trends Analysis Report 2023-2030 - Innovative Techniques Propel Global Protein Labeling Market Forward - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023

Protein labeling is undergoing a significant transformation, driven by the burgeoning interest in Post-translational Modification (PTM) studies.

Key Points: 
  • Protein labeling is undergoing a significant transformation, driven by the burgeoning interest in Post-translational Modification (PTM) studies.
  • The application of advanced quantification methods, such as iodoTMTzero Label Reagent, is facilitating the efficient detection of PTMs, propelling the market forward.
  • Biomedical research is at the forefront of driving growth in the global protein labeling market.
  • The surge in PTM studies, fueled by breakthroughs in protein expression quantification and innovative tagging strategies, is a pivotal factor.

Global Rat Model Market to Reach $2.41 Billion by 2030 with a CAGR of 7.06%: Key Insights and Growth Factors Unveiled

Retrieved on: 
Tuesday, October 31, 2023

The global rat model market size is expected to reach USD 2.41 billion by 2030., expanding at a CAGR of 7.06% from 2023 to 2030.

Key Points: 
  • The global rat model market size is expected to reach USD 2.41 billion by 2030., expanding at a CAGR of 7.06% from 2023 to 2030.
  • Genetically modified organisms are extensively used in research for identifying potential therapeutic targets and further validation of the same.
  • The extensive healthcare-based research has driven the market for understanding diseases and genetic illnesses of humans.
  • Increased spending on research and growing number of clinical trials are the key factors contributing to the market growth.

Aileron Therapeutics Announces Acquisition of Lung Therapeutics

Retrieved on: 
Tuesday, October 31, 2023

WALTHAM, Mass. and AUSTIN, Texas, Oct. 31, 2023 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx"), a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments. Immediately following the acquisition of Lung Tx, Aileron entered into a definitive agreement for the sale of shares of Aileron's Series X non-voting convertible preferred stock (the "Series X preferred stock") and warrants to purchase shares of Aileron's common stock in a private placement to a group of accredited investors led by Bios Partners ("Bios"), and including Nantahala Capital, as well as additional undisclosed investors. The private placement is expected to result in gross proceeds to Aileron of approximately $18 million before deducting placement agent fees and other offering expenses. Aileron intends to use the proceeds from the private placement primarily to complete the ongoing Phase 1b clinical study of LTI-03, a Caveolin-1-related peptide in development for the treatment of IPF, and for general corporate purposes. 

Key Points: 
  • and AUSTIN, Texas, Oct. 31, 2023 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx"), a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments.
  • "We are pleased to announce that after a thorough evaluation of strategic alternatives, we have completed the acquisition of Lung Therapeutics, which we believe represents a value-creation opportunity for Aileron's stockholders.
  • "Lung Therapeutics has built a promising clinical-stage pipeline for life-threatening lung conditions, and we believe in the ability of our combined companies to deliver value to both patients and stockholders."
  • I want to thank the board and entire team of Lung Therapeutics for all their hard work with this transaction."

TATAA Announces Formation of Scientific Advisory Board

Retrieved on: 
Tuesday, October 31, 2023

GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").

Key Points: 
  • GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").
  • "We are excited to have such a distinguished group of experts on our Scientific Advisory Board.
  • The Scientific Advisory Board demonstrates our commitment to delivering innovative solutions and exceptional services to our clients, and we look forward to working closely with them to achieve our goals."
  • said Dr. Sofia Adolfsson, Scientific Officer and Head of Bioinformatics at TATAA.

TATAA Announces Formation of Scientific Advisory Board

Retrieved on: 
Tuesday, October 31, 2023

GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").

Key Points: 
  • GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").
  • "We are excited to have such a distinguished group of experts on our Scientific Advisory Board.
  • The Scientific Advisory Board demonstrates our commitment to delivering innovative solutions and exceptional services to our clients, and we look forward to working closely with them to achieve our goals."
  • said Dr. Sofia Adolfsson, Scientific Officer and Head of Bioinformatics at TATAA.

Clarivate Report Reveals China Challenging U.S. Research Dominance, Signaling Future Research Ambitions

Retrieved on: 
Tuesday, October 31, 2023

LONDON, Oct. 31, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today released a report from the Institute for Scientific Information (ISI)™ which reveals that China's* research economy has seen a dramatic increase in quality and its research is increasingly valued beyond its borders. China is also diversifying beyond its traditional strengths in technology and physical sciences to focus on new areas such as biomolecular science.

Key Points: 
  • The report shows an acceleration in published research output, which increased five-fold between 2009 and 2021, well outpacing the U.S. and E.U.
  • While the U.S. remains a key international research partner, China is fostering closer collaboration with emerging research economies in the Middle East as well as many others.
  • Dr. Nandita Quaderi, Senior Vice President, Academia & Government at Clarivate said: "This latest ISI analysis demonstrates the huge potential of our research data and transformative intelligence to inform research assessment and research policy on China.
  • *In this report, the regional term China in technical analyses identifies the research activity of the People's Republic of China including Mainland China, Hong Kong and Macau.

Clarivate Report Reveals China Challenging U.S. Research Dominance, Signaling Future Research Ambitions

Retrieved on: 
Tuesday, October 31, 2023

LONDON, Oct. 31, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today released a report from the Institute for Scientific Information (ISI)™ which reveals that China's* research economy has seen a dramatic increase in quality and its research is increasingly valued beyond its borders. China is also diversifying beyond its traditional strengths in technology and physical sciences to focus on new areas such as biomolecular science.

Key Points: 
  • The report shows an acceleration in published research output, which increased five-fold between 2009 and 2021, well outpacing the U.S. and E.U.
  • Its proportion of published research with citation impact above the global average now matches the U.S. and Germany.
  • While the U.S. remains a key international research partner, China is fostering closer collaboration with emerging research economies in the Middle East as well as many others.
  • *In this report, the regional term China in technical analyses identifies the research activity of the People's Republic of China including Mainland China, Hong Kong and Macau.